Clinical Trial Update: EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating EXL01 for maintenance of steroid-induced response/remission in mild to moderate Crohn's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• EXL01

Snippet

Sponsor: Exeliom Biosciences | Conditions: Crohn Disease | Phase 1 | Status: TERMINATED